Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study-Reference-Cited by-同舟云学术

Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study

Published:2018-10 Issue:5 Volume:57 Page:661-664
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Bigazzi Federico,Sbrana Francesco,Berretti Daniele,Maria Grazia Zenti,Zambon Sabina,Fabris Antonia,Fonda Maurizio,Vigna Giovanni B.^ORCID,D’Alessandri Giovanna,Passalacqua Stefano,Dal Pino Beatrice,Pianelli Mascia,Luciani Roberta,Ripoli Andrea,Rafanelli Daniela,Manzato Enzo,Cattin Luigi,Sampietro Tiziana

Publisher

Elsevier BV

Subject

Hematology

Reference30 articles.

1. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status;Nordestgaard;Eur Heart J,2010

2. Lipoprotein(a) is associated with necrotic core progression of nonculprit coronary lesions in statin-treated patients with angina pectoris;Nozue;Lipids Health Dis,2014

3. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality;Erqou;JAMA,2009

4. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting;Ezhov;Atherosclerosis,2014

5. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology;Nordestgaard;Lipid Res,2016

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New insights into the therapeutic options to lower lipoprotein(a);European Journal of Clinical Investigation;2024-05-22

2. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?;International Journal of Molecular Sciences;2024-03-21

3. Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy;European Journal of Preventive Cardiology;2024-03-12

4. Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA);Nutrition, Metabolism and Cardiovascular Diseases;2023-10

5. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives;International Journal of Environmental Research and Public Health;2023-09-06